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levated blood pressure (BP), even
within the normal range, is associ-
ated with cardiovascular (CV) mor-
bidity and mortality. Therefore, the Joint
National Committee (JNC) VII intro-
duced the term “prehypertension” in the
general population, which is deﬁned as
BP levels of 120–139 mmHg and 80–89
mmHg for systolic and diastolic BP, re-
spectively (1). Prehypertension includes
two different categories of BP: normal
(systolic of 120–129 mmHg or diastolic
BP of 80–84 mmHg) and high-normal
(systolic of 130–139 mmHg or diastolic
BP of 85–89 mmHg). The risk of CV
events is increased by two- to fourfold
with the coexistence of hypertension and
type 2 diabetes. Lowering BP is particu-
larly effective in patients with type 2 dia-
betes. Therefore, guidelines recommend
lowering BP to below 130/80 mmHg in
diabetic patients. Thus, the term “prehy-
pertension” is inadequate for patients
with type 2 diabetes. It is clear from
guidelines that in diabetic patients, the
high-normal BP category of prehyperten-
sionshouldbepharmacologicallytreated.
However, there is no evidence that drug
treatment is beneﬁcial in the normal BP
category of prehypertension. Therefore,
despite the devastating effect of elevated
BP in type 2 diabetes, drug treatment is
not always recommended for all diabetic
patients with prehypertension.
Hypertension is perhaps best deﬁned
by the BP level that has a negative impact
on the CV system. Thus, numerical deﬁ-
nitions, although hotly debated by nu-
merous guideline committees, are not
helpful to practicing physicians. Recent
guidelines set the target level of BP for
uncomplicated hypertension to below
140/90 mmHg and in the diabetic hyper-
tensive patient to below 130/80 mmHg
(1,2). Solid evidence exists showing that
the beneﬁts of BP lowering are far more
pronounced in the diabetic than in the
nondiabetic hypertensive patient. In light
of the beneﬁts of BP lowering in diabetic
patients, there is a dilemma as to whether
diabetic patients with prehypertension
should be medically treated to lower BP. I
willendeavortoanalyzetheavailabledata
to determine what therapeutic approach
should be adopted for diabetic patients
with prehypertension.
RISK OF HYPERTENSION IN
DIABETES— Hypertensionisamajor
modiﬁable risk factor for CV morbidity
and mortality. Diabetes is associated with
ahighriskofCVdiseaseandistheleading
cause of end-stage renal disease, blind-
ness, and nontraumatic amputations in
western countries (3). Although the ef-
fects of diabetes and hypertension on the
CV system vary somewhat, and are often
distinct, their combined presence in the
same patient is destructive (4).
Coronary artery disease is far more
commonindiabetichypertensivepatients
than in patients suffering from hyperten-
sion or diabetes alone (5). For all 2,681
men in the PROCAM trial who had none
of the three risk factors (i.e., hyperten-
sion, diabetes, or hyperlipidemia), the
coronary artery disease incidence was
6/1,000 over 4 years. In contrast, the in-
cidence of coronary artery disease in par-
ticipants who were suffering from
hypertension or diabetes was 14 and 15
per 1,000 over 4 years, respectively.
When both risk factors were present in
the same patient, the incidence rate in-
creased to 48 per 1,000 (5).
Severalclinicalstudieshaveindicated
that diabetes is associated with cardio-
myopathy that is independent of ath-
erosclerotic coronary artery disease (6).
Congestive heart failure is substantially
increased in diabetic patients irrespective
of coronary artery disease and hyperten-
sion (7). The Framingham study data re-
vealed a fourfold greater incidence of
congestive heart failure in diabetic men
and an eightfold increase in diabetic
women, compared with nondiabetic sub-
jects (8). In the DIGAMI (Diabetes Melli-
tus Insulin-Glucose Infusion in Acute
Myocardial Infarction) trial, congestive
heart failure accounted for up to 66% of
mortality during the ﬁrst year postmyo-
cardial infarction in diabetic patients (9).
Longstanding hypertension leads to
the development of cardiomyopathy,
which is associated with impaired cardiac
function (10). We showed that in hyper-
tensivepatients,contractilitydeteriorated
as left ventricular mass increased (11). A
progressive decline in ventricular func-
tion may lead to congestive heart failure.
DatafromtheFraminghamstudyshowed
that hypertension was the primary cause
of congestive heart failure in 35% of cases
and played a role in this condition in an-
other 40% (12).
The coexistence of diabetes and hy-
pertension results in more severe cardio-
myopathy than would be expected with
either hypertension or diabetes alone
(10). Clinical studies with echocardiogra-
phyalsoshowedanincreasedleftventric-
ular mass in diabetic hypertensive
patients (13) increased septal and poste-
riorwallthicknessinpatientswithhyper-
tension and diabetes, compared with
nondiabetic hypertensive patients (13).
Prevalenceofleftventricularhypertrophy
was72%indiabetichypertensivepatients
and only 32% in the nondiabetic hyper-
tensive patients who had a similar degree
of hypertension. Because left ventricular
hypertrophy is known to predispose pa-
tients with hypertension to CV morbid
and fatal events, the ﬁnding of a high
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indiabetichypertensivepatientsmaypar-
tially explain their increased morbidity
and mortality. Cardiomyopathy of diabe-
tes and hypertension is associated with
impaired ventricular function and a high
prevalence of congestive heart failure
(10).
Diabetes is one of the leading causes
for end-stage renal disease (ESRD) (14).
Hypertension is a well-deﬁned risk factor
for end-stage renal disease and accounts
for 27% of all end-stage renal disease
cases in the U.S. and 33.4% of end-stage
renal disease cases among African Ameri-
cans (14).
When hypertension is superimposed
on diabetes, it accelerates the decrease in
renal function. Blood pressure control
can slow the progression of renal disease
in diabetic patients (15).
Diabetesadverselyaffectscerebrovas-
cular arterial circulation. The risk of
stroke is increased by 150–400% for pa-
tients with diabetes (16). In the Multiple
Risk Factor Intervention Trial, subjects
taking medications for diabetes were
threetimesaslikelytosufferastroke(17).
Inparticular,diabetesincreasestheriskof
strokeamongyoungerpatients.Theprev-
alence of diabetes increases the risk of
stroke-related dementia more than three-
fold (18), doubles the risk of recurrence,
and increases total and stroke-related
mortality (19).
Hypertension, mainly systolic, is
strongly and directly related to stroke in
all age-groups (20), and lowering BP re-
duces the rate of stroke remarkably (21).
The occurrence of diabetes more than
doubles the risk of stroke in hypertensive
patients (22), and lowering BP in these
patientsreducestheriskofstrokeby44%
(23).
Diabetes may cause diabetic reti-
nopathythatischaracterizedbyneovas-
cularization and formation of
microaneurysms. Hypertension acceler-
ates the development of diabetic retinop-
athy. Knowler et al. (24) found that in
diabetic subjects not taking insulin, the
incidence of exudates in those with sys-
tolic BP of 145 mmHg was more than
twice that of those with pressures of
125mmHg.Thecombinationofhyper-
tensive and diabetic retinopathy is often
devastating and remains one of the lead-
ing causes of blindness.
PREHYPERTENSION— A recent
meta-analysis showed that casual BP is
stronglyassociatedwithage-speciﬁcmor-
tality (20). The relationships between BP
and mortality exist over a wide BP range,
starting from 115/75 mmHg. On this ba-
sis, the JNC VII introduced a new cate-
gory of “prehypertension.” This category
is deﬁned as a systolic BP level of 120–
139 mmHg and/or diastolic BP level of
80–89 mmHg. Several studies showed
that “prehypertension” is common and is
associated with the metabolic syndrome
and other CV risk factors (25,26), such as
obesity, elevated triglycerides, elevated
LDL cholesterol, and low levels of HDL
cholesterol. Furthermore, during follow-
up, subjects with prehypertension are
more susceptible to developing true hy-
pertension and coronary atherosclerosis
(25,27). Prehypertension includes two
different categories of BP that are used by
the European Society of Hypertension:
normal BP (systolic 120–129 mmHg, or
diastolic 80–84 mmHg) and high-
normal BP (systolic 130–139 mmHg or
diastolic 85–89 mmHg) (2). Grotto et al.
(26) showed that subjects with high pre-
hypertension, which is equivalent to
high-normal BP, have elevated levels of
glucose, total cholesterol, triglycerides,
and BMI and lower levels of HDL choles-
terolthanthosewithlowprehypertension
equivalent to normal BP. Vasan et al. (28)
showedthattheriskforCVdiseaseis2.5-
and 1.6-fold higher among women and
men, respectively, with high-normal BP
than in those with optimal BP (120/80
mmHg). Thus, prehypertension is associ-
ated with other metabolic abnormalities
and increased CV risk. Within the prehy-
pertension group, there is further stratiﬁ-
cation into two risk categories: normal
and high-normal BP.
DIABETIC
PREHYPERTENSION— In pa-
tients with type 2 diabetes, elevated BP is
more harmful than in nondiabetic sub-
jects.Thereisclearevidencethatlowering
BP is more beneﬁcial in diabetic than in
nondiabeticpatients.Aggressivelowering
of BP is beneﬁcial in type 2 diabetes, even
in patients without hypertension. High-
normal BP or high prehypertension is
considered hypertension in type 2 diabe-
tes and requires antihypertensive treat-
ment. Regarding this issue, elsewhere we
suggested that diabetic prehypertension
should be deﬁned as systolic BP of 110–
129 mmHg and/or diastolic BP of 70–79
mmHg (29).
The question, therefore, should not
be whether to treat prehypertension in
patientswithtype2diabetes,butwhether
to initiate antihypertensive treatment in
diabetic patients with diabetic prehy-
pertension.
TREATMENT OF
PREHYPERTENSION— In the
general population, there are no outcome
studies showing any beneﬁt of drug treat-
ment in prehypertension. Only two stud-
ies evaluated the efﬁcacy of drug
treatment in prehypertension (30,31).
The Trial of Preventing Hypertension
(TROPHY) study investigated whether
pharmacologic treatment of prehyperten-
sion prevents or postpones stage 1 hyper-
tension (30). A total of 809 subjects with
high-normal BP (high prehypertension)
wererandomlyassignedtoreceive2years
of either candesartan (409 subjects) or
placebo (400 subjects), followed by 2
yearsofplaceboforeveryone.Allsubjects
were instructed to change their lifestyles
toreduceBP.Duringtheﬁrst2years,can-
desartan reduced the risk of incident hy-
pertension by 66.3% (P  0.001);
hypertension had developed in 154 sub-
jects in the placebo group and 53 of those
in the candesartan group. After 4 years,
candesartan reduced the risk of incident
hypertension by 15.6% (P  0.007); hy-
pertensionhaddevelopedin240subjects
in the placebo group and 208 of those in
the candesartan group. In the recent Pre-
vention of Hypertension study, using the
ACE inhibitor ramipril in patients with
high-normal BP (PHARAO), a total of
1,008subjectswithhigh-normalofﬁceBP
wererandomizedtotreatmentwitheither
ramipril (n  505) or placebo (n  503)
and were followed up for 3 years (31).
Treatment with ramipril reduced the risk
of progression to hypertension by 34.4%
(155 subjects with ramipril vs. 216 sub-
jects with placebo). Despite the reduction
in progression to hypertension, ramipril
failed to reduce CV events and death.
Both studies succeeded in showing that
blockers of the renin angiotensin system
reduce progression to hypertension, but
they did not show a reduction of CV
events. Further long-term studies with
additional antihypertensive agents are re-
quired to evaluate whether pharmacologi-
cal treatment can improve clinical
outcomesinpatientswithprehypertension.
TREATMENT OF DIABETIC
PREHYPERTENSION— Several
studies evaluated the effect of pharmaco-
logical treatment in diabetic patients with
normal BP (32,33). In the normotensive
Appropriate Blood Pressure Control in
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diabetic patients with baseline normal BP
(140/90 mmHg) were randomized to
intensive (10 mmHg below the baseline
diastolic BP) or moderate (80–89
mmHg) diastolic BP control. Over a
5-year follow-up period, intensive BP
control (average of 128/75 mmHg) was
associated with less progression to incip-
ient or overt diabetic nephropathy, less
progression to diabetic retinopathy, and
less incidence of stroke than moderate
(137/81 mmHg) BP control. In the recent
Action in Diabetes and Vascular disease
preterAx and diamicorN MR Controlled
Evaluation (ADVANCE) trial, 11,140
patients with type 2 diabetes were ran-
domized to treatment with a ﬁxed com-
bination of perindopril and indapamide
or matching placebo (32). After a mean of
4.3 years of follow-up, active treatment
(BP 136/73 mmHg) reduced the relative
risk of a major macrovascular or micro-
vascular event by 9%, compared with the
placebo treatment (BP 140/73 mmHg).
The authors stated that the study treat-
ment was not affected by the initial BP
levels.However,themeaninitialBPofthe
studied population was 145/81 mmHg,
which is clearly hypertension in type 2
diabetes, and 7,655 (68.5%) patients had
a history of current antihypertensive
treatment. Moreover, analysis of sub-
groups revealed that in patients with no
history of hypertension, active treatment
did not reduce CV events.
SHOULD WE USE
PHARMACOLOGICAL
TREATMENT IN DIABETIC
PREHYPERTENSION?— There is
no evidence that antihypertensive treat-
mentisbeneﬁcialinpatientswithdiabetic
prehypertension. Data from the U.K. Pro-
spective Diabetes Study (UKPDS)-23
showed that a 10-mmHg decrease in sys-
tolic BP was associated with a 12% reduc-
tion in risk of any complication related to
type2diabetes.ThelowerthesystolicBP,
the lower the risk of complications, and
no threshold of systolic BP was observed
for a substantive change in risk for any of
the outcomes examined. These ﬁndings
do not necessarily mean that we need to
force BP treatment to a goal 130/80
mmHg. When considering lowering the
BP goal in type 2 diabetes, and medically
treating patients with diabetic prehyper-
tension,thecostandbeneﬁtofdrugtreat-
ment should be taken into account. It
seems that the beneﬁt, if any, of lowering
BP in diabetic patients below 130/80
mmHg is marginal. Thus, it seems that
withthepresentevidence,itwouldbeun-
justiﬁed to recommend drug treatment in
diabetic prehypertension.
CONCLUSIONS— The deﬁnition of
prehypertension in type 2 diabetes is dif-
ferentfromthatinthegeneralpopulation.
High-normal BP (high prehypertension)
is considered hypertension in type 2 dia-
betes and requires drug treatment. How-
ever, diabetic-prehypertension requires
lifestyle modiﬁcation and not pharmaco-
logical treatment. Long-term studies with
antihypertensive treatment in diabetic
prehypertension will be beneﬁcial in
teaching us whether or not to modify our
current approach.
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